<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529411</url>
  </required_header>
  <id_info>
    <org_study_id>SOGUG2011/02</org_study_id>
    <nct_id>NCT01529411</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer</brief_title>
  <acronym>MAJA</acronym>
  <official_title>Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to evaluate the efficacy and safety of the drug vinflunine
      administered after the standard treatment of the combination gemcitabine+cisplatin, when it
      has reached stabilization or response of the disease, as the first treatment inmeditely after
      the diagnosis of advanced or metastatic urothelial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vinflunine is a drug recently approved in Europe for the treatment of advanced or metastatic
      urothelial cancer after platinum-failure. It has proved to improve the survival results
      compared with the best suportive care. In adition, the tolerability was favourable, specially
      for not leading appearance of neuropathy nor other cumulative toxic effects.

      In this study, it is proposed to test the feasibility, in terms of tolerability and efficacy
      of monotherapy with vinflunine in patients who, after completing the first-line
      cisplatin-based treatment for Transitional Cell Carcinoma of the Urothelial Tract (CCTU),
      have reached a stabilization or objective response. In order to have an adequate control
      group in the proposed design will be a phase II trial in which one group will receive
      standard management (follow-up until progression disease).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival.</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the Progression Free Survival (PFS) with vinflunine in maintenance monotherapy in patients with advanced or metastatic CCTU that has reached stabilization or objective response after completing 6 cycles with the combination cisplatin-gemcitabine in 1st line.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Carcinoma, Transitional Cell</condition>
  <arm_group>
    <arm_group_label>Vinflunine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance &lt; 60ml/min)
+ best suportive care, with regards clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best suportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best suportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <description>Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance &lt; 60ml/min).</description>
    <arm_group_label>Vinflunine</arm_group_label>
    <other_name>Javlor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Undefined (standard care)</intervention_name>
    <description>All the current interventions used by each institution for the study disease.</description>
    <arm_group_label>Best suportive care</arm_group_label>
    <other_name>undefined</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 &amp; &lt; 80

          -  Written informed consent given by the patient

          -  Diagnosis of urothelium cells transition cancer subsidiary locally advanced or
             metastatic resection

          -  One measurable target lesion minimum

          -  ECOG 0 or 1

          -  Stabilization or objective response after first-line treatment 6 cycles of
             cisplatin+gemcitabine

          -  Last administration of cisplatin and gemcitabine &lt; 6 weeks

          -  Maximum grade I toxicity

          -  Adequate functions of bone marrow, kidney and liver

          -  Absence psychological, family, sociological or geographical disorder or other
             condition

          -  Women of childbearing potential must be using a medically accepted method of
             contraception (i.e. oral contraceptives, intrauterine devices) to avoid pregnancy
             during the 2 months preceding the start of study treatment, throughout the study
             period and for up to 3 months after the last dose of study treatment in such a manner
             that the risk of pregnancy is minimised. Women of childbearing potential must have a
             negative serum or urine pregnancy test within 72 hours prior to the start of study
             treatment.

          -  Fertile men must be using an effective method of birth control if their partners are
             women of childbearing potential up to 3 months after last administration of study
             medication.

        Exclusion Criteria:

          -  ECOG &gt; 2

          -  Patients with age &gt; 80

          -  Patients with small cell carcinoma histology, lymphomas or sarcomas of the bladder.

          -  The patients that have received 7 or more cycles of a combination of cisplatin and
             gemcitabine in first line metastatic disease.

          -  Pregnant or lactating women or women with positive pregnancy test at screening,
             fertile sexual active women that did not use or do not wish or are unable to use an
             accepted method to prevent pregnancy during the 2 months prior to study treatment,
             during the study period and up to 3 months after the last dose of study treatment.
             Sexual active men who do not wish to use a method of birth during the study and up to
             6 months after the last dose of study treatment if their partners are women of
             childbearing age.

          -  Known brain metastases or meningeal involvement. CT Scan not required to rule this
             unless there is clinical suspicion of disease of the central nervous system.

          -  Peripheral neuropathy grade 2 according to NCI-CTC version 4.0 [Common Toxicity
             Criteria of the National Cancer Institute].

          -  Prior radiation to &gt; 30% of the bone marrow, radiation completed at least 30 days or
             current persistence of any adverse event.

          -  Other serious diseases or medical conditions like: systemic infection that required a
             systemic anti-infective treatment(grades 3 or 4 of the Common Toxicity Criteria NCI,
             version 4.03) and uncontrolled medical disorder, for example: patients with unstable
             angina or myocardial infarction within 6 months before registration or uncontrolled
             diabetes.

          -  Progressive Disease during 1st line treatment of advanced or metastatic disease with
             chemotherapy systemic cisplatin and gemcitabine.

          -  Patients who have received more than one line of treatment for metastatic disease.

          -  Patients who received cisplatin in monotherapy or in combination as neoadjuvant
             treatment, adjuvant after initial surgery of urothelial cancer.

          -  Patients treated with another investigational drug or treatment antineoplastic agent
             cisplatin or gemcitabine than within 30 days before randomization.

          -  Other cancers except basal skin cancer treated in an appropriate, cervical cancer in
             situ or other tumor a disease-free interval of 5 years.

          -  Inadequate renal function defined by a calculated clearance serum creatinine &lt; 40
             ml/min (Cockcroft-Gault).

          -  Known hypersensitivity to drug study or similar chemical structure drugs.

          -  Patients who require treatment with ketoconazole, itraconazole, ritonavir, amprenavir,
             indinavir, rifampin or phenytoin (any potent inhibitor or inducer of CYP3A4).

          -  Any concurrent chronic immunotherapy or prior organic allograft.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús García-Donas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Fundación Alcorcón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Font, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-Hospital Universitari Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquim Bellmunt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. del Mar - FIMIM (Fundació Institut Mar d´Investigacions Mèdiques)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Elda Virgen de la Salud</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO-Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO-Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundació Althaia</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hosp. Univ. de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. del Mar (Fundació Institut Mar d´Investigacions Mèdiques - FIMIM)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra (CUN)</name>
      <address>
        <city>Pamplona</city>
        <zip>31002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVO</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.sogug.es</url>
    <description>Sponsor´s web-site</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urothelium</keyword>
  <keyword>transitional</keyword>
  <keyword>carcinoma</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>tract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

